{"name":"Soleno Therapeutics, Inc.","slug":"soleno-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Placebo for DCCR","genericName":"Placebo for DCCR","slug":"placebo-for-dccr","indication":"DCCR-related conditions","status":"phase_3"},{"name":"VYKAT XR","genericName":"VYKAT XR","slug":"vykat-xr","indication":"Hypokalemia (low serum potassium)","status":"marketed"}]}],"pipeline":[{"name":"Placebo for DCCR","genericName":"Placebo for DCCR","slug":"placebo-for-dccr","phase":"phase_3","mechanism":"This drug is a placebo for DCCR, meaning it has no active therapeutic effect.","indications":["DCCR-related conditions"],"catalyst":""},{"name":"VYKAT XR","genericName":"VYKAT XR","slug":"vykat-xr","phase":"marketed","mechanism":"VYKAT XR is a sustained-release formulation of potassium that provides controlled delivery of potassium to treat hypokalemia.","indications":["Hypokalemia (low serum potassium)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNR1YtX1VEam9PcVBlUko3LVZxMlhXQ0hPSHZKQVJwU3ZLOWJFQ2xNRFFqMldhWno2OXdsN1RRYXh6Vk5PSVQ3U3dLZmt2TkpBSG1hdC1MaFpqYkhwMmZlZ0JRaVZuZkQ5SDZleDRrQy1FWi1KWUJhaF95WGZSVmpJQkpZSkVQYWJhNk5hYUVDeG9TZVVMekdiclgwcHBJTU50ZDJqN3ZxNWlmbG00MTktQzdDV2RVZw?oc=5","date":"2026-04-08","type":"pipeline","source":"TradingView","summary":"Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why - TradingView","headline":"Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOQjJqRnVfMVdLTFhGQV9yaEZZcmJteXZHTnMtdlhuRkNRcnJEdTZlUVdvdlZUemJNQ1M0NEM0VDRrQ0x1NXpnZjJ1M3g4VTNsZ0tKTU1wQy01SFJyYkRMOVJwNzFpdTBrQ0txcll0ZWhCZlhlQUFVTUpyODUxcFRzbG1WSVZrdFMweFJGendSTUpLMUcxTFYxMDktbWo4NDFvVlREWklOVlpHdmtkeGIxSjhwZGJDZTdiTFR5dFRJUTlKWXpQZE1rTmlkYjF2RXUtelc5aDBfdjNIRVRYVkx3OXB1emZRdUE?oc=5","date":"2026-04-06","type":"deal","source":"PR Newswire","summary":"Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PR Newswire","headline":"Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPNzdDNi1YNFVWdWxPUm1XWFlJdTFTdHY4Z0FSQWpyQ2kwUHZ1ZFdNc19XVUxsaDIxV3E1bDJlYVZaV1E5bElGdjl4TnBJeENHV0pvMjhIWGVPUC1ZazZQdW9RMUR6UWNob2hFRDFfMTR1QkdWVW5feERJRThzSk9uWUd6ZTBYVE1NWi1DMW1Wbl83cnFKOFFkaHFoMXhYdF9mZTNEWGVfaEJScW84bG96U3RHY3QxVG5o?oc=5","date":"2026-04-06","type":"deal","source":"Reuters","summary":"Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - Reuters","headline":"Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNZFZwOUlJVVRFbHJCSFdGNnBGNF9kblp5YTdUM3ZJVjg0aGJyNi13MU9Xem5mM0FzbHpYYXgxM1NyTTVyRzVPZ1FTeVJfb1c2R3RjbzRQSmZ3MFk5SEpLd2xzbGxqS3RUWm9tVEFNc3V2Ujk3UE0yM1JrU3N2bDRwLTd3TkdPMl81UzljMGtMQVNIeUlKVGJMNGZB?oc=5","date":"2026-04-06","type":"deal","source":"Pharmaceutical Executive","summary":"Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics | PharmExec - Pharmaceutical Executive","headline":"Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics | PharmExec","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNlowTW9qbmNjQWJzWjU4b04xMF9lcmtwNTEzdTFFdkMwWnh4N2J1NWZVa21Ca1J4b29EemYtMVJXaENUaUdQTk9TWE9ka2ZrRVdfWWtJN0drZTRqY1RIRG5PMmowNW9kTDRweXhVYk05T3cwUFFwX0xJNmZqdF81NzZZLWFLX2RacVlvYmVqR0h1T1JydFZCVlk3SEJRZFF4Vzl5QUExU0V5YzJ6bUhyVG5fX0cyNEdWMVVCZGpPUUQ2UQ?oc=5","date":"2026-04-06","type":"deal","source":"Fierce Pharma","summary":"Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout - Fierce Pharma","headline":"Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNQ3NDOEVweWlIQjYzdGZYTlBXWURGOERMZjB4R013OFlaRkpXdzdTa0ZIcVU1NGdCVjJBQ1dXQzRYU2RtM1JlYTFabnhKYXJsd2Vvam1KSkY2QVU1WjNMa3pZeXZuYlJIMGk2TE8wcDMzSUxDWDhXV3FsLVVsQjR6elVOVHBsaEtDOVVkZjdUUVltMnhyVDQ0dVo5SGxwcDNjdUw1Ql9ydGkxdU9tRHh4RXRBSXhhS280M1R6bGtHYkdnT1JxWTNSbXM4Q2JUcWE5?oc=5","date":"2026-04-06","type":"pipeline","source":"Proactive financial news","summary":"Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... - Proactive financial news","headline":"Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOT2REQzFmcHp0UWc0U2ozWXRnd2ZVaW42V3V1bGpscEpiSEo4anI2Q0hiejJDazlQWWJwWEFSLWp6Z3lpZnMwWml6bVZWNEtlc2N0aXJhNjVUY2FIM0lOS3hkMTVOaVJCNmdQaW9iUDR6S2tkRVEwTGdFV2laaVhlVGw4WTJrUmhmM1hOU0pld3J1NE9lYVJiVXQtM0oyazRoX2Q1UzBKcWNWQWRtU3BMVXN3cXM?oc=5","date":"2026-04-02","type":"trial","source":"National Today","summary":"Soleno Therapeutics Faces Class Action Lawsuit Over Drug Trial Concerns - National Today","headline":"Soleno Therapeutics Faces Class Action Lawsuit Over Drug Trial Concerns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQakVjWWkzZjBSZjg0M29kRHhCUS1kem10ZXJ3c3pPcFA5VXJHa0Q2MXdpcVhfY1k2T3o3c1hCeGlleUFwaXBXM1VFVFF0MU9lNEUzT242VjFiUlNWVHFUYW1EaHk0eEp6RE5xVkxiRV90bjhfbHpaSW9qZDZEemhSNTczQzI3bWxBOVpLUnFnekxyckNOZ2VSMTBOWmV6YXVDMGhPdGRNS3lQWjBHZlFyTHZNZ1U0cnBYemNXSjBmTkJvaG5VdEtNam1qQ0pGa3VjU2wwMHNHVkF6Zmd6aVFSZ1hVbDZMQnAtYWppNE1QZzFDWWhnc1E?oc=5","date":"2026-03-14","type":"pipeline","source":"PR Newswire","summary":"Soleno Therapeutics, Inc. (SLNO) Securities Fraud Class Action Lawsuit Filed; May 5, 2026, Lead Plaintiff Deadline - PR Newswire","headline":"Soleno Therapeutics, Inc. (SLNO) Securities Fraud Class Action Lawsuit Filed; May 5, 2026, Lead Plaintiff Deadline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQNDlFQWFURUVmMnRRVnFEVnJXdjVtNkIxUVY1N2VNT21uUWo3dnVVelNaWGQ5QS1wcG8xTFJiNlAtVi0wZGdjXy1BVnhTVUN6Z0lHZm9mWGVQaDJsb01fX0EzQ1FYX29aUXN1RmJTbFZXdHE0SjJlVHZCUlg2cGRFanlwSHplcWJ0anpjcXZ4ekRyNm5qeGtn?oc=5","date":"2026-01-14","type":"pipeline","source":"seekingalpha.com","summary":"Soleno Therapeutics: Why I’m Staying On The Sidelines (NASDAQ:SLNO) - seekingalpha.com","headline":"Soleno Therapeutics: Why I’m Staying On The Sidelines (NASDAQ:SLNO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQaHNyZWtjVnNRZzctdWE4VDVqNFRlR3oxSE05eGF0ZTB5aUFOTjhNYXc5VDJsUU9ib3NVZ2ozREpDWjhkUnpKZmhGQklhNXNGaUpUN0dwclFIY1kxS1l6bHRaaDh2Q3Q3ZmNtc2dJNnJoT1pIeGNGcVZ5U3BfMmV1VnBxeldPTnF0RWFQVXZuQQ?oc=5","date":"2026-01-08","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQMnYzREdBVGh6YnJ0c1N4V0F0dm9xLTVFYnB5blgwNFVJVmhTVjNoUHJWeUxFZG9zNjB4NmVLSFVjd1o4bk9CRTZ0SVBqT2s1LUp5SVV5amlXdHpKN1N4ZEdBbkZIR2lwNk83NWpJN0Iyci1SWlA0YzhBM0stZUJIUmRlWlRTTDBqRGdsME40R0E2WkIwYko3cG94U1BLT0lTdHp5UG96LVVZYzE2bWdHWXp0TmxsODVWMXhJbl9RNVVIZ0xZb2ZYU0Y1dnZTaFUt?oc=5","date":"2025-11-04","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Soleno Therapeutics Q3 2025 earnings beat expectations - Investing.com","headline":"Earnings call transcript: Soleno Therapeutics Q3 2025 earnings beat expectations","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPc1J3eUUtV1JWM1RDWXNzY2Q5dXNiT0pHc1FUZDc5V2JYSVNiTHhNU3VCVUszZlprV3BHbXl5c01nY0R1MTl5VXZRNVljdEh2Vi1oLUtuX0NHekRrOUM4SWFZRFM1NGJfSWROc0pWdDZqN0dDWGI3NGFoUkdtY1VrbWVPSXB1Ylda?oc=5","date":"2025-09-24","type":"pipeline","source":"Investor's Business Daily","summary":"Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily","headline":"Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}